Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Irinotecan in Cancers With DNA Repair Gene Mutations
NCT05694715Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- May 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in metastatic solid tumor (6 cohorts), sponsored by University of California, San Francisco. Primary endpoints: Percentage of participants with treatment-emergent adverse events at 30 days, Maximum Tolerated Dose at 30 days and 2 more. Started May 2023; status: recruiting.
02
Drugs
niraparib
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT05694715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694715.